Results for abirateronacetat translation from Slovenian to English

vpliv hrane na abirateronacetat
effect of food on abiraterone acetate

zdravilna učinkovina je abirateronacetat.
the active substance is abiraterone acetate.

zytiga 250 mg tablete abirateronacetat
zytiga 250 mg tablets abiraterone acetate

zdravilo zytiga vsebuje učinkovino abirateronacetat.
zytiga contains a medicine called abiraterone acetate.

abirateronacetat ni bil karcinogen pri podganjih samicah.
abiraterone acetate was not carcinogenic in female rats.

opazili so učinke na zunanja spolovila, vendar abirateronacetat ni bil tetatogen.
effects on the external genitalia were observed though abiraterone acetate was not teratogenic.

v 24-mesečni študiji karcinogenosti pri podganah je abirateronacetat zvečal pojavljanje novotvorb intersticijskih celic v testisih.
in a 24-month carcinogenicity study in the rat, abiraterone acetate increased the incidence of interstitial cell neoplasms in the testes.

pri bolnikih, ki so prejemali abirateronacetat, so poročali o hepatotoksičnosti z zvečanimi koncentracijami alt, ast in celokupnega bilirubina.
hepatotoxicity with elevated alt, ast and total bilirubin has been reported in patients treated with abiraterone acetate.

v študijah plodnosti pri samicah in samcih podgan je abirateronacetat zmanjšal plodnost, ki pa je po 4 do 16 tednih po ukinitvi izzvenela.
in fertility studies in both male and female rats, abiraterone acetate reduced fertility, which was completely reversible in 4 to 16 weeks after abiraterone acetate was stopped.

abirateronacetat se in vivo hitro pretvori v abirateron, ki je zaviralec biosinteze androgenov (glejte poglavje 5.1).
abiraterone acetate is rapidly converted in vivo to abiraterone, an androgen biosynthesis inhibitor (see section 5.1).

v blatu je mogoče najti predvsem nespremenjen abirateronacetat in abirateron (približno 55% oziroma 22% vnešenega odmerka).
the major compounds present in faeces are unchanged abiraterone acetate and abiraterone (approximately 55% and 22% of the administered dose, respectively).

v študiji 302 so pri 35 (6,5%) bolnikih, ki so prejemali abirateronacetat opazili 3. ali 4. stopnjo zvišanja koncentracij alt ali ast.
in study 302, grade 3 or 4 alt or ast elevations were observed in 35 (6.5%) patients treated with abiraterone acetate.

po peroralnem vnosu 14c-abirateronacetata v obliki kapsul se abirateronacetat hidrolizira v abirateron, ta pa se nato večinoma v jetrih presnavlja naprej, med drugim s sulfacijo, s hidroksilacijo in z oksidacijo.
following oral administration of 14c-abiraterone acetate as capsules, abiraterone acetate is hydrolysed to abiraterone, which then undergoes metabolism including sulphation, hydroxylation and oxidation primarily in the liver.

pri bolnikih, ki so prejemali abirateronacetat, so se pojavili naslednji neželeni učinki 3. stopnje po ctcae (verzija 3.0): hipokaliemija pri 3%; okužba sečil, zvišanje koncentracije alaninaminotransferaze, hipertenzija, zvišanje koncentracije aspartat-aminotransferaze, zlomi pri 2%, periferni edemi, srčno popuščanje in atrijska fibrilacija pri 1%.
the following ctcae (version 3.0) grade 3 adverse reactions occurred in patients treated with abiraterone acetate: hypokalaemia 3%; urinary tract infection, alanine aminotransferase increased, hypertension, aspartate aminotransferase increased, fractures 2%; peripheral oedema, cardiac failure, and atrial fibrillation 1% each.